Dynamical Behavior of Secondary Dengue Infection Model

Chai Jian Tay


With the increase of dengue cases in the last decades, efforts on controlling the dengue disease have been carried out. Dengvaxia, the first dengue vaccine developed by Sanofi Pasteur, was recommended by WHO for trial. The long-term safety follow-up indicates that the vaccine efficacy is higher in seropositive human population and there is an increase risk of severe dengue in vaccinated seronegative human. It is important to understand the dynamical behavior of dengue that includes both the seronegative and seropositive human population before performing vaccination. For such purpose, a secondary dengue infection model is developed and investigated in this paper. The basic reproduction number, Ro is derived and sensitivity analysis is performed to determine the most sensitive parameter in the model. The results indicate that Ro is the most sensitive to the ratio of mosquito to human, dengue transmission from human to mosquito, dengue transmission from mosquito to human and natural mortality of mosquito. It is also found that the ratio of seropositive to seronegative human population is 1.52 for a given set of parameter values at dengue endemic state. This would assist the authorities in deciding the proportion of seropositive and seronegative human population to be vaccinated. Numerical simulation results show that a decline in primary dengue infection is not associated with a decrease in secondary dengue infection. Therefore, the dengue control strategies should produce high efficacy in transmissibility reduction and ultimately reduce the DHF.

Full Text:



Back, A.T. and Lundkvist, A., 2013. Dengue viruses - an overview. Infection Ecology and Epidemiology, 3.

Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen, A.G., Moyes, C.L., Farlow, A.W., Scott, T.W. and Hay, S.I., 2012. Refining the global spatial limits of dengue virus transmission by evidence - based consensus. PLoS Neglected Tropical Diseases, 6(8): e1760.

Murray, N.E.A., Quam, M.B. and Wilder-Smith, A., 2013. Epidemiology of dengue: past, present and future prospects. Clinical Epidemiology, 5, pp.299-309.

Khan, A., Hassan, M. and Imran, M., 2014. Estimating the basic reproduction number for single-strain dengue fever epidemics. Infectious Diseases of Poverty, 3(12).

Hu, K., Thoens, C., Bianco, S., Edlund, S. Davis, M., Douglas, J. and Kaufman, J.H., 2013. The effect of antibody-dependent enhancement, cross immunity, and vector population on the dynamics of dengue fever. Journal of Theoretical Biology, 319(2013), pp.62-74.

Guzman, M.G., Alvarez, M. and Halstead S.B., 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of Virology, 158, pp.1445-1459.

Guzman, M.G. and Vazquez, S., 2010. The complexity of antibody-dependent enhancement of dengue virus infection. Viruses, 2, pp.2649-2662.

Katzelnick, L.C., Gresh, L., Halloran, M.E., Mercado, J.C., Kuan, G., Gordon, A., Balmaseda, A. and Harris, E., 2017. Antibodydependent enhancement of severe dengue disease in humans. Science, Doi: 10.1126/science.aan6836.

Lyon, 2016. First dengue vaccine approved in more than 10 countries. [pdf] Sanofi Pasteur. Available at: https://www.sanofipasteur.com/media/Project/One-Sanofi-Web/sanofipasteur-com/en/mediaroom/docs/PR 20161004_FirstDengueVaccineApprovedInMoreThan10Countries_EN.pdf [Accessed 15 August 2018].

Aguiar, M., Stollenwerk, N. and Halstead, S.B., 2018. Dengvaxia: age as surrogate for serostatus. The Lancet Infectious Diseases, 18(3), pp.245.

Aguiar, M., Halstead, S.B. and Stollenwerk, N., 2017. Consider stopping Dengvaxia administration without immunological screening. Expert Review of Vaccines, 16(4), pp.301-302.

Aguiar, M., Stollenwerk, N. and Halstead, S.B., 2016. The risk behind Dengvaxia recommendation. The Lancet Infectious Diseases, 16(8), pp.882-883.

Pang, T., Gubler, D., Goh, D.Y.T. and Ismail, Z., 2018. Dengue vaccination: a more balanced approach is needed. The Lancet Infectious Disease, 391(10121), pp.654.

World Health Organization, 2017. Updated questions and answers related to the dengue vaccine Dengvaxia and its use.

[pdf] Available at: http://www.who.int/immunization/diseases/dengue/QA_dengue_vaccine_22Dec2017.pdf?ua=1 [Accessed 01 November 2018].

Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau A., et al., 2018. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. The New England Journal of Medicine, 379, pp.327-340.

Ferguson, N.M., Rodriguez-Barraquer, I., Dorigatti, I., Mier-y-Teran-Romero, L., Laydon, D.J. and Cummings, D.A.T., 2016. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modelling optimal deployment. Science, 353, pp.1033-1036.

Garba, S.M., Gumel, A.B. and Bakar, M.R.A., 2008. Backward bifurcations in dengue transmission dynamics. Mathematical Biosciences, 215, pp.11-25.

Chen, S.C. and Hsieh, M.H., 2012. Modeling the transmission dynamics of dengue fever: implications of temperature effects. Science of the Total Environment, 431, pp.385-391.

Rodrigues, H.S., Monteiro, M.T.T., and Torres, D.F.M., 2014. Vaccination models and optimal control strategies to dengue. Mathematical Biosciences, 247, pp.1-12.

Ministry of Health Malaysia, 2016. Health facts 2016. [pdf] Available at: http://pqi.stats.gov.my/result.php?token=3eaa33fb6c88df5f795f852046d006f4 [Accessed on 12th August 2016].

Diekmann, O., Heesterbeek, J.A.P. and Roberts, M.G., 2010. The construction of next-generation matrices for compartmental epidemic models. Journal of the Royal Society Interface, 7, pp.873-885.

Chitnis, N., Hyman, J.M. and Cushing, J.M., 2008. Determining important parameters in the spread of Malaria through the sensitivity analysis of a mathematical model. Bulletin of Mathematical Biology, 70, pp.1272-1296.

Manore, C.A., Hickmann, K.S., Xu, S., Wearing, H.J. and Hyman, J.M., 2014. Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus. Journal of Theoretical Biology, 356, pp.174-191.

Liao, C.M., Huang, T.L., Cheng, Y.H., Chen, W.Y., Hsieh, N.H., Chen, S.C. and Chio, C.P., 2015. Assessing dengue infection risk in the southern region of Taiwan: implications for control. Epidemiology and Infection, 143, pp.1059-1072.

Pena, J.M., 2004. Characterizations and stable tests for the Routh-Hurwitz conditions and for total positivity. Linear Algebra and Its Applications, 393, pp.319-332.

Esteva, L. and Vargas, C., 1998. Analysis of a dengue disease transmission model. Mathematical Biosciences, 150(2), pp. 131-151.

World Health Organization, 2018. Revised SAGE recommendation on use of dengue vaccine. Available at: https://www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_dengue_vaccines_apr2018/en/ [Accessed on 18 March 2019].

Nagao, Y. and Koelle, K., 2008. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proceedings of the National Academy of Sciences, 105(6), pp. 2238-2243.

DOI: http://dx.doi.org/10.5614%2Fcbms.2019.2.1.1


  • There are currently no refbacks.

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

This journal published by: Indonesian Bio-Mathematical Society, Pusat Pemodelan Matematika dan Simulasi, Jalan Ganesa No. 10 Bandung 40116